OptimizeRx (OPRX) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $21.615M, down 17% YoY, while adjusted EBITDA rose to $6.295M from $5.107M.

• FY2026 revenue guidance was reduced to $87M–$93M; adjusted EBITDA guidance remained $21M–$25M.

• Early 2027 contracted revenue was tracking ~20% ahead YoY during RFP season, while Q4 conversion remained uncertain.

Financial highlights

• Q3 revenue was $21.615M vs. $26.067M a year earlier; 9M revenue was $61.963M vs. $77.190M.

• Q3 adjusted EBITDA rose to $6.295M from $5.107M despite lower revenue.

• Q3 expenses fell $5.1M YoY to $18.9M, including $0.7M of severance costs.

• Q3 GAAP net income was $1.195M, or $0.06 per share; adjusted net income was $3.835M, or $0.20 per diluted share.

• Q3 operating income was $2.670M vs. $2.071M a year earlier.

Outlook and guidance

• FY2026 revenue guidance was lowered to $87M–$93M; adjusted EBITDA guidance was maintained at $21M–$25M.

• 2026 contracted revenue was ~20% below the comparable prior year; more than 90% of revenue needed for the guidance midpoint was contracted, vs. a mid-90% range in prior years.

• Q4 delivery depends on timing and conversion of customer buy-ups; visibility into contracting, delivering and recognizing remaining budgets before year-end was limited.

• Early 2027 contracted revenue was tracking ~20% ahead YoY during RFP season; management said it was too early to provide 2027 guidance.

• Management expected FY2026 gross margin in the low-70% range and cited cost reductions as support for EBITDA guidance.